Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter.
GAAP net loss of ($4.2) million.
Record adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 million in the prior‑year quarter and an increase of 108% over $5.3 million in the sequential quarter.
Completed public offering of common stock for aggregate gross proceeds of $69 million.
Expanded Oaktree Loan from $100 million to $112.50 million.
Acquired certain commercial rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS.
Acquired North American commercial rights to VEVYE®, a novel FDA-approved drug labeled to treat both the signs and symptoms of dry eye disease.
Completed transfer of New Drug Application for VIGAMOX®.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.